Shinji Fukuda

Shinji Fukuda

Auto-generated profile, based on publicly available information

Shinji Fukuda

Department of Biochemistry, School of Dentistry, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya, 464-8650, Aichi, Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
JMJun Muto
Jun Muto
SFShinji Fukuda
Shinji Fukuda
KWKenji Watanabe
Kenji Watanabe
XDXiuju Dai
Xiuju Dai
TTTeruko Tsuda
Teruko Tsuda
KSKoji Sayama
Koji Sayama
Trehalose is the nonreducing disaccharide of glucose, evolutionarily conserved in invertebrates. The living skin equivalent (LSE) is an organotypic coculture containing keratinocytes cultivated on fibroblast-populated dermal substitutes. We demonstrated that human primary fibroblasts treated with highly concentrated trehalose promote significantly extensive spread of the epidermal layer of LSE without any deleterious effects. The RNA-seq analysis of trehalose-treated 2D and 3D fibroblasts at early time points revealed the involvement of the CDKN1A pathway, the knockdown of which significantly suppressed the upregulation ofDPT,ANGPT2,VEGFA,EREG, andFGF2. The trehalose-treated fibroblasts were positive for senescence-associated β-galactosidase. Finally, transplantation of the dermal substitute with trehalose-treated fibroblasts accelerated wound closure and increased capillary formation significantly in the experimental mouse wounds in vivo, which was canceled by the CDKN1A knockdown. These data indicate that high-concentration trehalose can induce the senescence-like state in fibroblasts via CDKN1A/p21, which may be therapeutically useful for optimal wound repair.

15 May 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SSShinya Sato
Shinya Sato
MMMegumi Miyazaki
Megumi Miyazaki
SFShinji Fukuda
Shinji Fukuda
YMYukiko Mizutani
Yukiko Mizutani
YMYoichi Mizukami
Yoichi Mizukami
SIShintaro Inoue
Shintaro Inoue
Cutaneous hyaluronan (HA) is depolymerized to intermediate sizes in the extracellular matrix, and further fragmented in the regional lymph nodes. Previously, we showed that the HA-binding protein involved in HA depolymerization (HYBID), also known as KIAA1199/CEMIP, is responsible for the first step of HA depolymerization. Recently, mouse transmembrane 2 (mTMEM2) with high structural similarity to HYBID was proposed to be a membrane-bound hyaluronidase. However, we showed that the knockdown of human TMEM2 (hTMEM2) conversely promoted HA depolymerization in normal human dermal fibroblasts (NHDFs). Therefore, we examined the HA-degrading activity and function of hTMEM2 using HEK293T cells. We found that human HYBID and mTMEM2, but not hTMEM2, degraded extracellular HA, indicating that hTMEM2 does not function as a catalytic hyaluronidase. Analysis of the HA-degrading activity of chimeric TMEM2 in HEK293T cells suggested the importance of the mouse GG domain. Therefore, we focused on the amino acid residues that are conserved in active mouse and human HYBID and mTMEM2 but are substituted in hTMEM2. The HA-degrading activity of mTMEM2 was abolished when its His248 and Ala303 were simultaneously replaced by the corresponding residues of inactive hTMEM2 (Asn248 and Phe303). In NHDFs, enhancement of hTMEM2 expression by proinflammatory cytokines decreased HYBID expression and increased hyaluronan synthase 2-dependent HA production. The effects of proinflammatory cytokines were abrogated by hTMEM2 knockdown. A decreased HYBID expression by interleukin-1β and transforming growth factor-β was canceled by hTMEM2 knockdown. In conclusion, these results indicate that hTMEM2 is not a catalytic hyaluronidase, but a regulator of HA metabolism.

22 February 2006 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
MAMasahiko Abematsu
Masahiko Abematsu
TKTetsushi Kagawa
Tetsushi Kagawa
SFShinji Fukuda
Shinji Fukuda
TIToshihiro Inoue
Toshihiro Inoue
HTHirohide Takebayashi
Hirohide Takebayashi
Tetsuya TagaTetsuya Taga
Tetsuya Taga

20 April 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HNHironao Nakayama
Hironao Nakayama
HOHidetaka Ohnuki
Hidetaka Ohnuki
MNMasako Nakahara
Masako Nakahara
HNHisayo Nishida-Fukuda
Hisayo Nishida-Fukuda
TSTomohisa Sakaue
Tomohisa Sakaue
CKChiaki Kusumoto
Chiaki Kusumoto

3 February 2020 in Organic Letters
Verified
Journal Article
Closed access
YLYu Li
Yu Li
ZSZachary M. Sandusky
Zachary M. Sandusky
RVRajender Vemula
Rajender Vemula
QZQi Zhang
Qi Zhang
BWBulan Wu
Bulan Wu
George A O'DohertyGeorge A O'Doherty
George A O'Doherty

1 January 2021 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
EWEric B. Wright
Eric B. Wright
SFShinji Fukuda
Shinji Fukuda
MLMingzong Li
Mingzong Li
YLYu Li
Yu Li
George A O'DohertyGeorge A O'Doherty
George A O'Doherty
DLDeborah A. Lannigan
Deborah A. Lannigan
Identifying isoform-specific inhibitors for closely related kinase family members remains a substantial challenge. The necessity for achieving this specificity is exemplified by the RSK family, downstream effectors of ERK1/2, which have divergent physiological effects. The natural product, SL0101, a flavonoid glycoside, binds specifically to RSK1/2 through a binding pocket generated by an extensive conformational rearrangement within the RSK N-terminal kinase domain (NTKD). In modelling experiments a single amino acid that is divergent in RSK3/4 most likely prevents the required conformational rearrangement necessary for SL0101 binding. Kinetic analysis of RSK2 association with SL0101 and its derivatives identified that regions outside of the NTKD contribute to stable inhibitor binding. An analogue with an n-propyl-carbamate at the 4” position on the rhamnose moiety was identified that forms a highly stable inhibitor complex with RSK2 but not with RSK1. These results identify a SL0101 modification that will aid the identification of RSK2 specific inhibitors.